Rationale: Individuals with cystic fibrosis (CF) experience frequent acute pulmonary exacerbations, which lead to decreased lung function and reduced quality of life.
Cystic fibrosis (CF) is the most common life-shortening inherited disease in white individuals and affects approximately 30,000 people in the United States (1) . Advances in care for individuals with CF have resulted in dramatic improvements in survival, but people with CF still have debilitating symptoms and die far too early (2, 3) . Acute pulmonary exacerbations (PEs) are frequent and central events in the lives of individuals with CF. They result in permanent loss of lung function, worse quality of life, and shortened survival (4) (5) (6) (7) (8) .
Several studies have shown that in approximately 25% of exacerbations, patients do not return to within 90% of their baseline lung function after treatment for the exacerbation (9, 10) . One factor associated with poor response to exacerbation treatment may be longer time from symptom onset to exacerbation treatment, suggesting that delayed treatment results in worse treatment outcomes. There is also evidence suggesting that CF centers that see patients more frequently and treat patients more aggressively (e.g., with more antibiotic use) provide better clinical outcomes (11, 12) .
Most individuals with CF do not measure lung function or objectively track symptoms at home and contact their health care providers only during routinely scheduled appointments or if their symptoms worsen to a point that they feel they need treatment. This approach could lead to delays in exacerbation treatment, thus preventing important health outcomes, as seen in other studies (13, 14) .
We hypothesized that use of a protocol consisting of electronic home monitoring of FEV 1 and respiratory symptoms, as well as notifying care teams when patients had objective evidence of deterioration, would result in less decline in lung function over 12 months than in a group that received usual care. To test this, we performed a multicenter, nonblinded, randomized clinical trial of a protocol for early intervention in CF exacerbation.
Methods Study Design and Population
We conducted the eICE (Early Intervention in Cystic Fibrosis Exacerbation) study, a 1-year, randomized, nonblinded, multicenter, two-arm trial that ran from October 6, 2011, to July 7, 2015 , and involved adolescents and adults with CF, to assess whether early treatment of CF PEs was beneficial. Participants with CF were randomized 1:1 to either an early intervention (EI) arm or a usual care (UC) arm. The EI arm participants used home-based spirometers and patient-reported respiratory symptoms (using the Cystic Fibrosis Respiratory Symptom Diary [CFRSD]) (15) , completed twice weekly via the Viasys AM2 device (CareFusion, Yorba Linda, CA) to identify and trigger the treatment of PEs. The AM2 system alerted sites to contact patients for an acute PE evaluation whenever (1) FEV 1 values (in liters) fell by greater than 10% from baseline or (2) CFRSD worsened from baseline in two or more of eight respiratory symptoms. The UC arm participants, in contrast, had quarterly CF visits in addition to acute visits based on calls from the participant to the clinic triage telephone line (see earlier publication [16] ). The study is registered with www.clinicaltrials.gov (NCT01104402). The institutional review boards at each participating center approved the study.
The 52-week duration of the study consisted of five in-person clinic visits (see online supplement and Figure E1 in the online supplement). Eligibility for the study required that participants be at least 14 years of age, be clinically stable at baseline, and have FEV 1 percent predicted greater than 25%. After confirmation of eligibility, participants were randomized using an adaptive randomization algorithm (see online supplement) (17) .
Primary and Secondary Outcomes
The primary outcome variable was the 52-week change in FEV 1 volume (in liters). Pulmonary function testing was performed in accordance with American Thoracic Society standards (18) (19) (20) . See Table 1 and the online supplement for details of secondary outcome measures.
Statistical Analysis
Our primary hypothesis was that the EI arm participants would have a lower rate of FEV 1 decline over 52 weeks than the UC arm. In the primary analysis, we used a linear mixed effects model to estimate the 
Results

Recruitment and Follow-up
Of the 276 screened participants, 267 passed the eligibility criteria and were randomized (the ITT population): 135 to the EI arm and 132 to the UC arm ( Figure 1 ; see Figure E2 and Table E1 ). After enrolling 267 adolescents and adults with CF, the DMC recommended stopping recruitment because of a projected inability for the study to detect a difference between the EI and UC arms. Twenty percent (54 of 267) of participants withdrew from the study, with more withdrawals occurring in the EI arm (33 of 135 [24%]) than in the UC arm (21 of 132 [16%]). Across groups, the reasons for withdrawals were comparable and distributed as follows: 57% (n = 31) were due to subject decision, 20% (n = 11) were lost to follow-up, and 22% (n = 12) withdrew for other reasons.
The mean follow-up times were 46.8 weeks per participant in the EI arm compared with 50.9 weeks per participant in the UC arm. The two study arms were well matched with respect to demographic and clinical characteristics at baseline (Table 2) . Overall, 49% of the participants were female; 94% were white; 45% were F508del homozygous; and the mean age was 27 years, with 29% younger than 18 years of age.
Home Spirometry Adherence
Adherence with once-weekly data transmission was 50%, with 67 of 135 participants using the device at least once per week in more than 80% of their follow-up weeks. Adherence with twice-weekly transmission, however, was lower, with only 19% (26 of 135) of participants being greater than 80% adherent. A total of 524 alarms among 97 participants (72%) in the EI arm required physician follow-up (see online supplement for reasons for alarms).
Symptoms triggered the alarms less than home spirometry did.
Primary Endpoint
Absolute change in mean FEV 1 volume (in liters) from baseline to Week 52 in the EI arm was 20.08 L (95% CI, 20.13 to 20.03; P = 0.002), as compared with a 20.07-L change in the UC arm (95% CI, 20.13 to 20.02; P = 0.006) ( Figure 2A ). Covariate adjusted analysis of the primary endpoint showed no difference between study arms in terms of the 52-week mean change in FEV 1 slope (mean difference, 0.00 L; 95% (Table E2) . Also, there was no difference in effect between those who had high adherence and those subjects without high adherence to the intervention (mean difference in FEV 1 , 0.02 L; 95% CI, 20.09 to 0.12; P = 0.776) (see Table E3 ).
Secondary Efficacy Endpoints
Absolute change in mean FEV 1 (Figures 2B and E4) .
The prevalence of Pseudomonas aeruginosa at baseline (Table 2) did not differ between treatment arms, and the prevalence of P. aeruginosa postbaseline as captured at routine clinic visits was comparable between study arms (46% P. aeruginosa-positive in EI arm vs. 51% P. aeruginosa-positive in UC arm; difference, 25%; 95% CI, 219 to 8%; P = 0.411). Similarly, the prevalence of Staphylococcus aureus was not significantly different postbaseline between study arms (34% S. aureus-positive in EI arm vs. 30%
S. aureus-positive in UC arm; difference, 4%; 95% CI, 29 to 16%; P = 0.658). There was also no significant difference between study arms in terms of newly emergent P. aeruginosa or S. aureus over the followup period.
Of 135 participants in the EI arm, 101 (75%) experienced a protocol-defined PE, as compared with 92 (70%) of 132 participants in the UC arm (difference, 5%; 95% CI, 26 to 17%; P = 0.412). The EI arm was associated with a significantly higher hazard ratio (HR) for time to first PE and increased risk for subsequent PE (time to first PE HR, 1.45; 95% CI, 1.09 to 1.93; P = 0.011; time to subsequent PE HR, 1.34; 95% CI, 0.95 to 1.89; P = 0.091) (see Figure  E5 ). Hospitalization event rates were not significantly different between study arms (0.64 hospitalizations/participant-year in EI arm vs. 0.59 in UC arm; relative risk, 0.90; 95% CI, 0.65 to 1.23; P = 0.509).
Acute visits were much more likely to occur in the EI arm than in the UC arm (participants with at least one acute visit, 77 [57%] in EI arm vs. 38 [29%] in UC arm; difference, 28%; 95% CI, 16 to 40%) ( Table 3 ). More than twice as many acute visits occurred in the EI arm as in the UC arm (153 in EI arm vs. 64 in UC arm). Similar proportions of acute visits in each study arm fulfilled our protocol-defined The denominator for percentages is based on the total number of acute visits in each study arm. ‡
The denominator for percentages is based on the number of acute visits meeting/not meeting protocol-defined PE.
criteria for an acute PE. The main difference between the treatment arms was that the EI arm received a higher proportion of oral antibiotics as the treatment for protocol-defined PEs and a lower proportion of intravenous antibiotics than the UC arm (Table 3) . We found that, regarding PEs at both acute visits at the start of treatment and 2-week follow-up spirometry, fewer patients in the EI arm recovered to 5% of baseline FEV 1 percent predicted compared with the UC arm (28 of 60 acute visits in EI arm vs. 5 of 24 visits in UC arm) (see Table E4 ).
Adverse Events
The number of participants reporting at least one serious adverse event was similar across the two study arms (27% [n = 37] in EI arm vs. 28% [n = 37] in the UC arm) (see Table E3 ). All serious adverse events were deemed unrelated to study treatment. The EI arm had 1,580 adverse events (AEs) among 124 (92%) participants, whereas the UC arm had 1,307 AEs among 120 (91%) participants (rate ratio, 1.29; 95% CI, 1.19 to 1.38; P , 0.001) (Table E5) . One participant in the UC arm had a lung transplant, and two participants in the UC arm had non-respiratory-related life-threatening AEs. Independent of alarms or treatment allocation, most participants initiated oral antibiotics at least once during the course of the study, with no significant difference between study arms (92% in EI arm vs. 91% in UC arm; difference, 1%; 95% CI, 26 to 8%; P = 0.830). Despite differences in how exacerbations were treated (Table 3) , no significant differences were seen between study arms in the proportion receiving inhaled or intravenous antibiotics at least once for the duration of the study, with or without a protocol-defined exacerbation.
Quality-of-Life Surveys and Protocol Burden
Participants in the EI arm had significantly fewer respiratory symptoms than the UC arm participants as measured by the CFRSD (52-wk mean change in EI arm vs. UC arm, 0.45 vs. 4.56; difference, 24.1; 95% CI, 27.8 to 20.5; P = 0.028). The model-based estimate of the 52-week difference between study arms for slope of change in CFRSD scores was not statistically significant, however (mean, 22.5; 95% CI, 25.7 to 0.6; P = 0.577). Although the EI arm subjects had greater improvement in the Cystic Fibrosis Questionnaire-Revised respiratory domain scores from baseline to Week 52, the difference was not statistically significant (52-wk mean change in EI arm vs. UC arm, 20.44 vs. 23.07; difference, 2.6; 95% CI, 21.8 to 7.1; P = 0.244) (21) . Among participants who completed the study, the EI arm scored the protocol as significantly more burdensome (0-10 scale) than the UC arm (mean score in EI arm vs. UC arm, 2.9 vs. 0.6; P , 0.001). Subjects in the EI arm had significantly worse burden scores than patients completing the study (mean burden score, 4.45 among withdrawals vs. 2.92 among completers; P = 0.026).
Discussion
The primary objective of this randomized trial was to determine whether an intervention of home spirometry and home symptom monitoring would lead to earlier detection of CF PEs, which would in turn lead to earlier exacerbation treatment and result in slower decline in FEV 1 over 12 months. Importantly, the DMC recommended stopping recruitment because of a projected inability for the study to detect a difference between the treatment arms. Although acute PEs were more frequent in the EI arm, the decline in FEV 1 was small in both study arms and was not significantly different. There were trends toward greater improvement in BMI, respiratory symptoms, and quality of life in the EI arm, but these differences did not reach significance. The intervention was associated with an increased burden that may have led to decreased adherence to the intervention. This is the first large-scale, multicenter, randomized trial of a home monitoring intervention in CF. Earlier studies of home monitoring in CF showed encouraging results, and home monitoring has demonstrated efficacy in patients with other disease states, such as lung transplants (22) . A retrospective study was performed in the late 1980s by investigators at the University of Minnesota with 50 individuals with CF (23). Twenty-five participants were selected randomly from a group that had used home monitoring, and they were matched to 25 participants who had not done home monitoring. Over 4 years, FEV 1 declined from 73.1% predicted to 70.1% predicted in the home monitoring group (not significant) and from 72.3% predicted to 60.8% (P , 0.001) in the control group. More recently, in an Italian study of telehealth in 16 individuals with CF, investigators reported a significant increase in FEV 1 compared with a matched control group (24) . Although these were small observational studies, the results suggest that home monitoring was acceptable to patients, did not adversely affect patients, and may have resulted in beneficial health effects. However, these studies were not randomized, and they may have been subject to selection bias. It is likely that individuals who were receptive to home spirometry and followed through with it for prolonged periods of time had characteristics that were different from a selected control group. Factors such as treatment adherence and social support are extremely important in CF and could not be controlled for in the aforementioned studies. Our study differed in that it was a randomized, multicenter clinical trial, which removed selection bias from the use of home monitoring. Integrating devices in the home has been evaluated for other aspects of CF care centered in Australia (25) (26) (27) . These studies were pilot studies that may fail to be validated in a broader population much like ours. In CF, achieving adherence to medications, much less extra home monitoring, can be very challenging when extended to a broader population (28) .
Despite encouraging results of earlier studies in CF, our study did not demonstrate clinical efficacy and was unlikely to do so with continued enrollment (29) . There are other factors that may explain the negative results of the present study. Adherence with the EI protocol was lower than desired, with only 19% of participants in the intervention arm transmitting their home data twice weekly 80% of the time or greater. However, adherence with once-weekly data transmission was 50% using the device at least once per week on more than 80% of the follow-up weeks, and a total of 524 alarms among 97 participants (72%) in the EI arm required physician follow-up. Thus, even with lessthan-ideal adherence to the intervention, the intervention did lead to clinical encounters and a shorter time to diagnosis of a protocol-defined PE. In addition, a subgroup analysis of only the participants with high adherence failed to show significant results for the primary endpoint (Table E3) . Although this was a rigorously conducted clinical trial, the design was meant to approximate actual clinical care. The inclusion criteria were broad, and the treatment of PEs was not protocolized. Even though more exacerbations were detected in the EI arm, treatment of the PEs was more likely to be with oral antibiotics. This could point to potentially diminished efficacy of oral antibiotics to treat PEs. In fact, as noted above, approximately 47% of the subjects in the EI arm failed to recover to within 5% of baseline in terms of FEV 1 percent predicted as compared with only 21% in the UC arm. Despite this fact, 34% of patients in the EI arm did not require acute courses of antibiotics during the study, compared with 36% in the UC arm. Our findings suggest that simply detecting exacerbations more frequently is not sufficient to improve outcomes; improving the approach to management may be key to improving outcomes after PEs. Also, on the basis of subgroup analyses, low adherence with the protocol does not appear to explain our negative results.
One explanation for our negative results could be that, once detected, treatment of the acute exacerbation was suboptimal in the EI arm. Of the patients who had an acute visit, 67% were treated with oral antibiotics in the EI arm as compared with 43% in the observation arm at the time of diagnosis of an acute exacerbation. Given that more PEs were treated with intravenous antibiotics and hospitalizations in the UC arm, the oral antibiotics potentially prevented events that would otherwise have led to use of intravenous antibiotics. Currently, optimal care of an acute PE is not known. This includes number of antibiotics, duration of antibiotics, and location of delivery of antibiotics (at home or inpatient) (30) . Thus, identifying PEs alone may not be enough; one needs to optimize management of these events.
Our study did have limitations that could influence the interpretation of the results. First, we encountered a number of challenges with the home monitoring equipment that posed a barrier to some participants. Participants were required to connect the AM2 device to a computer via a serial port cable, and many computer hardware and software incompatibilities were encountered during the trial. There were considerable improvements in computer and communications technology during the study period, and future studies of this nature should use devices with more streamlined data transmission capabilities. Novel technologies and electronic monitoring could markedly enhance the intervention by lowering the burden of monitoring. Next, the study threshold for triggering a notification of an exacerbation was selected on the basis of pilot data, but it was meant to be a compromise that would not burden patients with falsepositive alarms. The symptom threshold was triggered less frequently than the home spirometry threshold. It is possible that choosing other cutoffs to detect an exacerbation may have led to different results. However, the alarms that were chosen did identify events more often and earlier during the study in the EI arm; the choice of alarm also would lead most clinicians to consider treating a PE (a 10% drop in spirometry and/or a change in baseline symptoms of two or more of the eight respiratory symptoms in the CFRSD). An additional limitation was that we could not easily blind the intervention; such a design feature could have influenced a positive study but is unlikely to have influenced a negative study. Another possible limitation is that the enrolled patients had relatively preserved lung function, with only 38% of the population having an FEV 1 less than 75% of predicted; we cannot rule out that the intervention would be efficacious in those with moderate to severe lung disease.
One additional limitation is worth noting. The study was powered to detect a 72-ml difference with 80% power. Our study was stopped early by the DMC on the basis of an unplanned futility analysis. In our final results, we found a mean difference in the slope of FEV 1 between the EI arm and the UC arm of 0.00 L (95% CI, 20.07 to 0.07). Thus, we could not exclude a 70-ml improvement with our intervention or a 70-ml decrement in our intervention compared with the UC arm. A number of current therapeutics that are used in the care of patients with CF have impacts on lung function that are only slightly larger than our a priori treatment effect. Oral azithromycin improved lung function by 94 ml (95% CI, 0.023 to 0.165) (31) , and inhaled hypertonic saline improved FEV 1 by 68 ml (95% CI, 3 to 132 ml), with no change in the primary endpoint: slope of FEV 1 decline (32). However, we felt that to integrate such an approach in CF care of home monitoring, which is associated with clear patient and caregiver burden, we would need to demonstrate clear superiority. In addition, the decline in lung function (approximately 3.5% over 52 wk) observed across both arms appeared large but was more likely an artifact of the study design. At baseline, all subjects were required to be clinically stable (an inclusion criterion), whereas at postbaseline, no such requirement was made. Slightly more than half of all subjects (144 of 267) had a postbaseline visit that met the protocoldefined PE criteria. The 52-week change in FEV 1 percent predicted in the remaining 123 subjects was 20.8% in the EI arm versus 21.5% in the UC arm (n = 84; difference, 0.7%; 95% CI, 21.9 to 3.3%; P = 0.601).
What can we take away from this largescale home monitoring trial in CF? Importantly, our study demonstrated that use of a home symptom and spirometry intervention can be effective for detecting more CF exacerbations with a shorter time to first exacerbation. This may have led to minor improvements in symptoms and BMI, though it did not translate to improved pulmonary outcomes. A better understanding of the underlying pathophysiology leading to CF PEs is essential to developing better approaches to prevention and treatment of exacerbations. Though this study was negative, it demonstrated that home monitoring with spirometry and a symptom diary is feasible and effective for detecting more acute exacerbations at an earlier time period than usual care. Further studies are needed to develop a better approach to treating exacerbations once they are detected. n Author disclosures are available with the text of this article at www.atsjournals.org.
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